Skip to main content
SpringerLink
Log in

New Therapeutic Approaches: Rationale and Results

  • Chapter
Motor Neuron Disease

Abstract

Although amyotrophic lateral sclerosis (ALS) remains an enigmatic disease, advances in understanding its pathogenesis have accelerated in recent years. Attempts to treat patients with ALS have become equally vigorous in the past decade. Although it is possible that specific treatment of ALS will become available only after the pathogenesis is discovered, therapeutic trials could also provide clues to the aetiology of this disorder (Mitsumoto et al. 1988). Progress in therapeutic trials also has been accelerated by newly developed quantitative techniques to assess objectively the possible therapeutic effects of new treatments (Andres et al. 1987, 1988; Brooks et al. 1991; Sufit et al. 1987). At the same time the need for critical understanding of the natural course of ALS has been emphasized (Munsat et al. 1988; Ringel et al. 1993). Public awareness of the disease has increased and patients’ wishes to try new therapeutic modalities have also facilitated the use of therapeutic trials. We expect to have a greater number of therapeutic trials in the coming years. In this chapter we shall review the rationale and results of recent therapeutic trials.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Akiguchi I, Kato T, Sugiyama H (1984) Trials of L-cysteine, TRH and 5-HTP in amyotrophic lateral sclerosis. Clin Neurol (Tokyo) 24: 1270–1273

    CAS  Google Scholar 

  • Albers GW, Goldberg MP, Choi DW (1992) Do NMD A antagonists prevent neuronal injury? Yes. Arch Neurol 49: 418–420

    PubMed  CAS  Google Scholar 

  • Albin RL, Greenamyre JT (1992) Alternative excitotoxic hypotheses. Neurology 42: 733–738

    PubMed  CAS  Google Scholar 

  • Allaoua H, Chaudieu I, Krieger C et al. (1992) Alterations in spinal cord excitatory amino acid receptors in amyotrophic lateral sclerosis patients. Brain Res 579: 169–172

    PubMed  CAS  Google Scholar 

  • ALS CNTF Treatment Study (ACTS) Group (Brooks BR, Cedarbaum JM, Mitsumoto H, Neville H, Pestronk A 1992 ) A phase I ascending-dose tolerability and pharmacokinetic study of recombinant human ciliary neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis (abstract). Neurology

    Google Scholar 

  • Andres PL, Thibodeau LM, Finison LJ, Munsat L (1987) Quantitative assessment of neuromuscular deficit in ALS. Neurol Clin 5: 125–141

    PubMed  CAS  Google Scholar 

  • Andres PL, Finison LJ, Conlon T, Thibodeau LM, Munsat TL (1988) Use of composite scores (megascores) to measure deficit in amyotrophic lateral sclerosis. Neurology 38: 405–408

    PubMed  CAS  Google Scholar 

  • Appel SH (1981) A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer disease. Ann Neurol 10: 499–505

    PubMed  CAS  Google Scholar 

  • Appel SH, Stockton-Appel V, Stewart SS, Kerman RH (1986) Amyotrophic lateral sclerosis: associated clinical disorders and immunological evaluations. Arch Neurol 43: 234–238

    PubMed  CAS  Google Scholar 

  • Appel SH, Stewart SS, Appel V et al. (1988) A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis. Arch Neurol 45: 381–386

    PubMed  CAS  Google Scholar 

  • Appel SH, Engelhardt JI, Garcia J, Stefani E (1991) Immunoglobulins from animal models of motor neuron disease and from human amyotrophic lateral sclerosis patients passively transfer physiological abnormalities to the neuromuscular junction. Proc Natl Acad Sci USA 88: 647–651

    PubMed  CAS  Google Scholar 

  • Appelbaum JS, Salazar-Grueso EF, Richard JG et al. (1991) Dextromethorphan in the treatment of ALS: a pilot study. Neurology 41 (Suppl 1): 393

    Google Scholar 

  • Aquilonius S-M, Askmark H, Ebendal T, Gilberg P-G (1992) No re-expression of high-affinity nerve growth factor binding sites in spinal motor neurons in amyotrophic lateral sclerosis. Eur Neurol 32: 216–218

    PubMed  CAS  Google Scholar 

  • Arakawa Y, Sendtner M, Thoenen H (1990) Survival effect of ciliary neurotrophic factor (CNTF) on chick embryonic motoneurons in culture: comparison with other neurotrophic factors and cytokines. J Neurosci 10: 3507–3515

    PubMed  CAS  Google Scholar 

  • Beghi E, Fiordelli E, Gerardo OS et al. (The Italian ALS Study Group) (1993) Branched-chain amino acids and amyotrophic lateral sclerosis: a treatment failure? Neurology 43:2466–2470

    Google Scholar 

  • Bensimon G, Lacomblez, L, Meininger V and the ALS/Riluzole Study Group (1994). A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 330: 585–591

    PubMed  CAS  Google Scholar 

  • Blin O, Pouget J, Aubrespy G et al. (1991) A double-blind placebo-controlled trial of L-threonine in amyotrophic lateral sclerosis. J Neurol 239: 79–81

    Google Scholar 

  • Bradley WG (1990) Critical review of gangliosides and thyrotropin-releasing hormone in peripheral neuromuscular diseases. Muscle Nerve 13: 833–842

    PubMed  CAS  Google Scholar 

  • Bradley WG, Hedlund W, Cooper C (1984) A double-blind controlled trial of bovine brain gangliosides in amyotrophic lateral sclerosis. Neurology 34: 1079–1082

    PubMed  CAS  Google Scholar 

  • Braunstein GD, Reviczky AL (1987) Serum insulin-like growth factor-I levels in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 50: 792–794

    PubMed  CAS  Google Scholar 

  • Brooke MH (1989) Thyrotropin-releasing hormone in ALS: are the results of clinical studies inconsistent? Ann NY Acad Sci 553: 422–430

    PubMed  CAS  Google Scholar 

  • Brooke MH, Florence JM, Heller SL et al. (1986) Controlled trial of thyrotropin-releasing hormone in amyotrophic lateral sclerosis. Neurology 36: 146–151

    PubMed  CAS  Google Scholar 

  • Brooks BR (1989) A summary of the current position of TRH in ALS therapy. Ann NY Acad Sci 553: 431–460

    PubMed  CAS  Google Scholar 

  • Brooks BR, Sufit RL, Montgomery GK, Beaulieu DA, Erickson LM (1987) Intravenous thyrotropin- releasing hormone in patients with amyotrophic lateral sclerosis: Dose-response and randomized concurrent placebo-controlled pilot studies. Neurol Clin 5: 143–158

    Google Scholar 

  • Brooks BR, Sufit RL, DePaul R et al. (1991) Design of clinical therapeutic trials in amyotrophic lateral sclerosis. Adv Neurol 56: 422–430

    Google Scholar 

  • Brown RH, Hauser SL, Harrington H, Weiner HL (1986) Failure of immunosuppression with a 10 to 14-day course of high-dose intravenous cyclophosphamide to alter the progression of amyotrophic lateral sclerosis. Arch Neurol 43: 383

    PubMed  Google Scholar 

  • Buchan AM (1992) Do NMD A antagonists prevent neuronal injury? No. Arch Neurol 49: 420–421

    PubMed  CAS  Google Scholar 

  • Caroscio JT, Cohen JA, Zawodniak J et al. (1986) A double-blind, placebo-controlled trial of TRH in amyotrophic lateral sclerosis. Neurology 36: 141–145

    PubMed  CAS  Google Scholar 

  • Choi DW (1987) Dextrorphan and dextromethorphan attenuate glutamate neurotoxicity. Brain Res 403: 333–336

    PubMed  CAS  Google Scholar 

  • Choi DW, Koh J, Peters S (1988) Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists. Neuroscience 8: 185–196

    PubMed  CAS  Google Scholar 

  • Clarke KA, Parker AJ, Stirk GC (1984) Motoneuron excitability during antidromically evoked inhibition after administration of a thyrotrophin-releasing hormone ( TRH) analogue. Neuropeptides 4: 403–411

    Google Scholar 

  • Committee on Health Care Issues (1987) Current status of thyrotropin-releasing hormone therapy in amyotrophic lateral sclerosis. Ann Neurol 22: 541–543

    Google Scholar 

  • Conomy JP, Gerhard G, Goren H, Braun W, Barna B (1980) Plasmapheresis in the treatment of amyotrophic lateral sclerosis. Neurology 30: 356

    Google Scholar 

  • Conradi S, Ronnevi LO (1985) Cytotoxic activity in the plasma of amyotrophic lateral sclerosis (ALS) patients against normal erythrocytes: quantitative determinations. J Neurol Sci 68: 135–145

    PubMed  CAS  Google Scholar 

  • Conradi S, Ronnevi LO (1987) Effect of immunosuppression on cytotoxic activity in amyotrophic lateral sclerosis. Clin Neuropharmacol 10: 280–286

    PubMed  CAS  Google Scholar 

  • Conradi S, Ronnevi LO, Nise G, et al. (1982a) Long-term penicillamine-treatment in amyotrophic lateral sclerosis with parallel determination of lead in blood, plasma and urine. Acta Neurol Scand 65: 203–211

    PubMed  CAS  Google Scholar 

  • Conradi S, Ronnevi LO, Norris IH (1982b) Motor neuron disease and toxic metals. Adv Neurol 36: 201–231

    PubMed  CAS  Google Scholar 

  • Corbett AJ, Griggs RC, Moxley RT III (1982) Skeletal muscle catabolism in amyotrophic lateral sclerosis and chronic spinal muscular atrophy. Neurology 32: 550–552

    PubMed  CAS  Google Scholar 

  • Corbo M, Quanttrini A, Lugarese A et al. (1992) Patterns of reactivity of human anti-GMla antibodies with spinal cord and motor neurons. Ann Neurol 32: 487–493

    PubMed  CAS  Google Scholar 

  • Cureton TK (1972) The physiological effects of wheat germ oil on humans in exercise. Forty-two physical training programs using 894 humans. CC Thomas, Springfield IL

    Google Scholar 

  • Currier RD, Haerer AF (1968) Amyotrophic lateral sclerosis and metallic toxins. Arch Environ Health 17: 712–719

    PubMed  CAS  Google Scholar 

  • Cwik VA, Mitsumoto H (1992) Postpoliomyelitis syndrome. In: Smith RA (ed) Handbook of amyotrophic lateral sclerosis. Marcel Dekker, New York, pp 77–92

    Google Scholar 

  • Dalakas MC, Aksamit A J, Madden DL, Sever JL (1986) Administration of recombinant human leukocyte alpha2-interferon in patients with amyotrophic lateral sclerosis. Arch Neurol 43: 933–935

    PubMed  CAS  Google Scholar 

  • Dau PC (1984) Plasmapheresis, therapeutic or experimental procedure? Arch Neurol 41: 647–653

    PubMed  CAS  Google Scholar 

  • Davis S, Aldrich TH, Valenzuela DM et al. (1991) The receptor for ciliary neurotrophic factors. Science 253: 59–63

    PubMed  CAS  Google Scholar 

  • de Jong JMBV, Den Hartog Jager WA, Posthumus Meyjes FE et al. (1988) N-acetylcysteine and N-acetylmethionine treatment of amyotrophic lateral sclerosis (ALS) and of rapidly progressive motor neuron disease (MND). In: Tsubaki T, Yase Y (eds) Amyotrophic lateral sclerosis. Elsevier, Amsterdam, pp 313–318

    Google Scholar 

  • Delbono O, Garcia J, Appel SH (1991) IgG from amyotrophic lateral sclerosis affects tubular calcium channels of skeletal muscle. Am J Physiol 260: C1347–C1351

    PubMed  CAS  Google Scholar 

  • Deng, HX, Hentati A, Tainer J A et al. (1993) Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science 261: 1047–1051

    PubMed  CAS  Google Scholar 

  • Drachman DB, Chaundhry V, Cornblath D et al. (1994) Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Ann Neurol 35: 142–150

    PubMed  CAS  Google Scholar 

  • Drachman DB, Kuncl RW (1989) Amyotrophic lateral sclerosis: an unconventional autoimmune disease? Ann Neurol 26: 269–274

    PubMed  CAS  Google Scholar 

  • Duarte F, Binet S, Lacomblez L et al. (1991) Quantitative analysis of monoclonal immunoglobulins in serum of patients with amyotrophic lateral sclerosis. J Neurol Sci 104: 88–91

    PubMed  CAS  Google Scholar 

  • Duchen LW, Strich SJ, Falconer DS (1968) An hereditary motor neurone disease with progressive denervation of muscle in the mouse: The mutant ‘wobbler’. J Neurol Neurosurg Psychiatry 31: 535–542

    Google Scholar 

  • Duncan MW, Kopin IJ, Garruto RM, Lavine L, Markey SP (1988) 2-amino-3(methylamino)-propionic acid in cycad-derived foods is an unlikely cause of amyotrophic lateral sclerosis/parkinsonism. Lancet ii:631–632

    Google Scholar 

  • Ebendal T, Asmark H, Aquilonius S-M (1989) Screening for neurotrophic disturbances in amyotrophic lateral sclerosis. Acta Neurol Scand 79: 188–193

    PubMed  CAS  Google Scholar 

  • Endo T, Scott DD, Stewart SS et al. (1984) Antibodies to glycosphingolipids in patients with multiple sclerosis and SLE. J Immunol 132: 1793–1797

    PubMed  CAS  Google Scholar 

  • Engel WK (1989) High-dose TRH treatment of neuromuscular disease: summary of mechanisms and critique of clinical studies. Ann NY Acad Sci 553: 462–472

    PubMed  CAS  Google Scholar 

  • Engel WK, Siddique T, Nicholoff JT (1983) Effect on weakness and spasticity in amyotrophic lateral sclerosis of thyrotropin-releasing hormone. Lancet ii: 73–75

    Google Scholar 

  • Engel WK, Spiel RH (1985) Prolonged at-home treatment of motor neuron disorders with self- administered subcutaneous (sc) high-dose TRH. Neurology 35 (Suppl 1): 106–107

    Google Scholar 

  • Engelhardt JI, Appel SH (1990) IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis. Arch Neurol 47: 1210–1216

    PubMed  CAS  Google Scholar 

  • Engelhardt JI, Appel SH, Killian JM (1989) Experimental autoimmune motorneuron disease. Ann Neurol 26: 368–376

    PubMed  CAS  Google Scholar 

  • Engelhardt J, Joo F (1986) Immune-mediated guinea pig model for lower motor neuron disease. J Neuroimmunol 12: 279–290

    PubMed  CAS  Google Scholar 

  • Faden A, Holaday JW, Jacobs TP (1981) Thyrotropin-releasing hormone improves neurological recovery after spinal trauma in cats. N Engl J Med 305: 1063–1067

    PubMed  CAS  Google Scholar 

  • Faden A, Jacobs TP, Smith MT (1984) Thyrotropin-releasing hormone in experimental spinal injury: Dose response and late treatment. Neurology 34: 1280–1284

    PubMed  CAS  Google Scholar 

  • Fallis RJ, Weiner LP (1982) Further studies in search of a virus in amyotrophic lateral sclerosis. Adv Neurol 36: 355–361

    PubMed  CAS  Google Scholar 

  • Färkkilä M, Iivanainen M, Roine R (1984) Neurotoxic and other side effects of high-dose interferon in amyotrophic lateral sclerosis. Acta Neurol Scand 69: 42–46

    Google Scholar 

  • Feldman EL, Bromberg MB, Albers JW et al. (1991) Immunosuppressive treatment of multifocal motor neuropathy. Ann Neurol 30: 397–401

    PubMed  CAS  Google Scholar 

  • Festoff BW (1983) Occurrence of reduced alpha2-macroglobulin and lowered protease inhibiting capacity in plasma of amyotrophic lateral sclerosis patients. Ann NY Acad Sci 421: 369–376

    PubMed  CAS  Google Scholar 

  • Festoff BW, Crigger NJ (1979) Therapeutic trials in amyotrophic lateral sclerosis: a review. In: Mulder DW (ed) The diagnosis and treatment of amyotrophic lateral sclerosis. Houghton Mifflin, Boston, pp 337–366

    Google Scholar 

  • Florini JR (1987) Hormonal control of muscle growth. Muscle Nerve 10: 577–598

    PubMed  CAS  Google Scholar 

  • Freddo L, Yu RK, Latov N et al. (1986) Gangliosides GM, and GDlb are antigens for IgM M-protein in a patient with motor neuron disease. Neurology 36: 454–458

    PubMed  CAS  Google Scholar 

  • Garruto RM, Yanagihara R, Gajdusek DC (1985) Disappearance of high-incidence amyotrophic lateral sclerosis and parkinsonism-dementia on Guam. Neurology 35: 193–198

    PubMed  CAS  Google Scholar 

  • Garruto RM, Swyt C, Yanagihara R et al. (1986) Intraneuronal co-localization of silicon with calcium and aluminum in amyotrophic lateral sclerosis and parkinsonism with dementia of Guam. N Engl J Med 317–711

    Google Scholar 

  • Gillberg PG, Aquilonius SM, Eckernas SA et al. (1982) Choline acetyltransferase and substance P-like immunoreactivity in the human spinal cord: changes in amyotrophic lateral sclerosis. Brain Res 250: 394–397

    PubMed  CAS  Google Scholar 

  • Gorio A, Carmignoto G, Ferrari G (1982) Axon sprouting stimulated by gangliosides: a new model for elongation and sprouting. In: Tapport MM, Gorio A (eds) Gangliosides in neurological and neuromuscular function, development and repair. Raven Press, New York, pp 177–195

    Google Scholar 

  • Gowers WR (1902) A lecture on abiotrophy. Lancet i: 1003–1007

    Google Scholar 

  • Greenamyre JT (1986) The role of glutamate in neurotransmission and in neurologic disease. Arch Neurol 43: 1058–1063

    PubMed  CAS  Google Scholar 

  • Growdon JH, Cohen EL, Wurtman RJ (1977) Treatment of brain disease with dietary precursors of neurotransmitters. Ann Intern Med 86: 337–339

    PubMed  CAS  Google Scholar 

  • Guiloff RJ, Eckland DJA, Demaine C et al. (1987a) Controlled acute trial of a thyrotropin-releasing hormone analogue (RX77368) in motor neuron disease. J Neurol Neurosurg Psychiatry 50: 1359–1370

    PubMed  CAS  Google Scholar 

  • Guiloff RJ, Stélberg E, Eckland DJA, Lightman SL (1987b) Electrophysiological observations in patients with motor neuron disease receiving a thyrotropin-releasing hormone analogue (TX77368). J Neurol Neurosurg Psychiatry 50: 1633–1640

    PubMed  CAS  Google Scholar 

  • Guiloff RJ, Modarres-Sadeghi H, Stålberg, Rogers H (1988) Short-term stability of single motor unit recordings in motor neuron disease: a macro EMG study. J Neurol Neurosurg Psychiatry 51: 671–676

    PubMed  CAS  Google Scholar 

  • Gurney ME, Yamamoto H, Kwon Y (1992) Induction of motor neuron sprouting in vivo by ciliary neurotrophic factor and basic fibroblast growth factor. J Neurosci 12: 3241–3247

    PubMed  CAS  Google Scholar 

  • Hagg T, Quon D, Higaki J et al. (1992) Ciliary neurotrophic factor prevents neuronal degeneration and promotes low affinity NGF receptor expression in the adult rat CNS. Neuron 8: 145–158

    PubMed  CAS  Google Scholar 

  • Harrington H, Hallett M, Tyler HR (1984) Ganglioside therapy for amyotrophic lateral sclerosis: a double-blind controlled trial. Neurology 34: 1083–1085

    PubMed  CAS  Google Scholar 

  • Hawley RJ, Kratz R, Goodman RR et al. (1987) Treatment of amyotrophic lateral sclerosis with TRH analog DN1417. Neurology 37: 715–717

    PubMed  CAS  Google Scholar 

  • Hayashi H, Suga M, Satake M, Tsubaki T (1980) Reduced glycine receptor in the spinal cord in amyotrophic lateral sclerosis. Ann Neurol 9: 292–294

    Google Scholar 

  • Helgren ME, Friedman B, Kennedy M et al. (1992) Ciliary neurotrophic factor ( CNTF) delays motor impairments in the Mnd mouse, a genetic model for motor neuron disease. Soc Neurosci Abstr 18: 618

    Google Scholar 

  • Hokfelt T, Fuxe K, Johannsson O, Jeffcoate S, White N (1975) Thyrotropin-releasing hormone ( TRH)- containing nerve terminals in certain brain stem nuclei and in the spinal cord. Neurosci Lett 1: 133–139

    Google Scholar 

  • Hollander D, Pradas J, Kaplan R et al. (1992) Long-term high-dose dextromethorphan in amyotrophic lateral sclerosis. Ann Neurol 32: 201

    Google Scholar 

  • Holmlund TH, Mitsumoto H, Greene T et al. (1992) The effect of ciliary neurotrophic factor (CNTF) on spontaneously degenerating motor neurons in wobbler mice. Neurology 42 (Suppl 3): 369

    Google Scholar 

  • House AO, Abbott RJ, Davidson DLW et al. (1978) Response to penicillamine of lead concentration in CSF and blood in patients with motor neurone disease. BMJ iii:1684

    Google Scholar 

  • Hugon J, Tabaraud F, Rigaud M, Vallat JM, Dumas M (1989) Glutamate dehydrogenase and aspartate aminotransferase in leukocytes of patients with motor neuron disease. Neurology 39: 956–958

    PubMed  CAS  Google Scholar 

  • Ikeda K, Mitsumoto H, Wong V, Lindsay RM, Cedarbaum JM (1994) Morphological changes correlate with functional improvement following ciliary neurotrophic factor (CNTF) treatment of motor neuron disease in the wobbler mouse (abstract). Neurology (in press)

    Google Scholar 

  • Imoto K, Saida K, Iwamura K, Saida T, Nighitani (1984) Amyotrophic lateral sclerosis: a double-blind crossover trial of thyrotropin-releasing hormone. J Neurol Neurosurg Psychiatry 47: 1332–1334

    CAS  Google Scholar 

  • Ip NY, Nye SH, Boulton TG et al. (1992) CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 signal transducing receptor component gp 130. Cell 69: 1121 - 1123

    PubMed  CAS  Google Scholar 

  • Ip NY, Yancopoulos GD (1994) Ciliary neurotrophic factor and its receptor complex. Prog Growth Factor Res 4 (in press)

    Google Scholar 

  • Iwasaki Y, Ikeda K, Kinoshita M (1991) Plasma amino acid levels in patients with amyotrophic lateral sclerosis. J Neurol Sci 105: 1–4

    Google Scholar 

  • Jackson IM, Adelman LS, Munsat TL, Forte S, Lechan R (1986) Amyotrophic lateral sclerosis: thyrotropin-releasing hormone and histidyl proline diketopiperazine in the spinal cord and cerebrospinal fluid. Neurology 36: 1218–12223

    PubMed  CAS  Google Scholar 

  • Jerusalem F, Fresmann J (1985) Comparison of treatment trials in ALS between thyrotrophin-releasing hormone (TRH) and TRH-derivative orotyl-L-histidyl-L-prolineamide. J Neurol 232 (Suppl): 35

    Google Scholar 

  • Jerusalem F, Fresmann J, Sayn H, Schulz G (1988) A double-blind, placebo-controlled trial of bestatin in amyotrophic lateral sclerosis (ALS). In: Tsubaki T, Yase Y (eds) Amyotrophic lateral sclerosis. Elsevier, Amsterdam, pp 333–338

    Google Scholar 

  • Jones TM, Yu R, Antel JP (1982) Response of patients with amyotrophic lateral sclerosis to testosterone therapy: endocrine evaluation. Arch Neurol 39: 721–722

    PubMed  CAS  Google Scholar 

  • Kaji R, Shibasaki H, Kumura J (1992) Multifocal demyelinating motor neuropathy: cranial nerve involvement and immunoglobulin therapy. Neurology 42: 506–509

    PubMed  CAS  Google Scholar 

  • Kameyama M (1980) Cyanide metabolism in the nervous disorder, with special reference to motor neuron disease. Clin Neurol (Tokyo) 20: 99–1007

    Google Scholar 

  • Kardon FC, Winokur A, Utiger RD (1977) Thyrotrophin-releasing hormone ( TRH) in rat spinal cord. Brain Res 122: 578–581

    Google Scholar 

  • Kato T, Kameyama M, Nakamura S, Inada M, Sugiyama H (1985) Cyanide metabolism in motor neuron disease. Acta Neurol Scand 72: 151–156

    PubMed  CAS  Google Scholar 

  • Kelemen J, Hedlund W, Murray-Douglas P, Munsat TL (1982) Lecithin is not effective in amyotrophic lateral sclerosis. Neurology 32: 315–316

    PubMed  CAS  Google Scholar 

  • Kelemen J, Hedlund W, Orlin JB, Berkman EM, Munsat TL (1983) Plasmapheresis with immunosuppression in amyotrophic lateral sclerosis. Arch Neurol 40: 752–753

    PubMed  CAS  Google Scholar 

  • Kerkhoff H, Jennekens FGI, Troost D, Veldman H (1991) Nerve growth factor receptor immunostaining in the spinal cord and peripheral nerves in amyotrophic lateral sclerosis. Acta Neuropathol 81: 649–656

    PubMed  CAS  Google Scholar 

  • Kishimoto T, Akira S, Taga T (1992) Interleukin-6 and its receptor: A paradigm for cytokines. Science 258: 593–596

    Google Scholar 

  • Krieger C, Melmed C (1982) Amyotrophic lateral sclerosis and paraproteinemia. Neurology 32: 896–898

    PubMed  CAS  Google Scholar 

  • Kurland LT (1972) An appraisal of the neurotoxicity of cycad and the etiology of amyotrophic lateral sclerosis on Guam. Fed Proc 31: 1540–1542

    PubMed  CAS  Google Scholar 

  • Kuther G, Struppler A (1986) Therapieversuch der amyotrophischen lateralsklerose mit N-acetylcystein. Fortschr Myol 8: 51–57

    Google Scholar 

  • Kyle RA, Finkelstein S, Elvback LR, Kurland LT (1972) Incidence of monoclonal proteins in a Minnesota community with a cluster of multiple myeloma. Blood 40: 719–724

    PubMed  CAS  Google Scholar 

  • Lacomblez L, Bouche P, Bensimon G, Meininger V (1989) A double-blind, placebo-controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis. Neurology 39: 1635–1637

    PubMed  CAS  Google Scholar 

  • Lange DJ, Trojaborg W, Latov N et al. (1992) Multifocal motor neuropathy with conduction block: is it a distinct clinical entity? Neurology 42: 497–505

    PubMed  CAS  Google Scholar 

  • Latov H, Hays AP, Donofrio PD et al. (1988) Monoclonal IgM with unique specificity to gangliosides GM1 and GDlb and to lacro-N-tetraose associated with human motor neuron disease. Neurology 38: 763–768

    PubMed  CAS  Google Scholar 

  • Lechan RM, Snapper SB, Jacobson S et al. (1984) The distribution of thyrotropin-releasing hormone ( TRH) in the Rhesus monkey spinal cord. Peptides 5: 185–194

    PubMed  CAS  Google Scholar 

  • LeRoith D, Clemmons D, Nissley P, Rechler MM (1992) Insulin-like growth factors in health and disease. HIN conference. Ann Intern Med 116: 854–862

    Google Scholar 

  • Lin LFH, Mismer D, Lile JD et al. (1989) Purification, cloning and expression of ciliary neurotrophic factors ( CNTF ). Science 246: 47–56

    Google Scholar 

  • Lipton SA (1989) Growth factors for neuronal survival and process regeneration: implications in the mammalian central nervous system. Arch Neurol 46: 1241–1248

    PubMed  CAS  Google Scholar 

  • Lisak RP (1984) Plasma exchange in neurologic diseases. Arch Neurol 41: 654–657

    PubMed  CAS  Google Scholar 

  • Malessa S, Leigh PN, Bertel O et al. (1991) Amyotrophic lateral sclerosis: glutamate dehydrogenase and transmitter amino acids in the spinal cord. J Neurol Neurosurg Psychiatry 54: 984–988

    PubMed  CAS  Google Scholar 

  • Manaker S, Winokur A, Rhodes CH, Rainbow TC (1985) Autoradiographic localization of thyrotrophin-releasing hormone receptors in the rat central nervous system. J Neurosci 5: 167–174

    PubMed  CAS  Google Scholar 

  • Manaker S, Caine SB, Winokur A (1988) Alterations in receptors for thyrotropin-releasing hormone, serotonin, and acetylcholine in amyotrophic lateral sclerosis. Neurology 38: 1464–1474

    PubMed  CAS  Google Scholar 

  • Manthorpe M, Skaper S, Adler R et al. (1980) Cholinergic neurotrophic factors: Fractionation properties of an extract from selected chick embryonic eye tissues. J Neurochem 34: 69–75

    PubMed  CAS  Google Scholar 

  • Masiakowski P, Liu H, Radziejewski C et al. (1991) Recombinant human and rat ciliary neurotrophic factors. J Neurochem 57: 1003–1012

    PubMed  CAS  Google Scholar 

  • McMorris FA, Smith TM, DeSalvo S et al. (1986) Insulin-like growth factor-I/somatomedin C: a potent inducer of oligodendrocyte development. Proc Natl Acad Sci USA 83: 822–826

    PubMed  CAS  Google Scholar 

  • Messer A, Strominger NL, Mazurkiewicz JE (1987) Histopathology of the late-onset motor neuron degeneration ( Mnd) mutant in the mouse. J Neurogen 4: 201–213

    Google Scholar 

  • Miller SC, Warnick J, (1989) Protirelin (thyrotropin-releasing hormone) in amyotrophic lateral sclerosis. Arch Neurol 46: 330–335

    PubMed  CAS  Google Scholar 

  • Mitsumoto H (1988) Clinical trials of thyrotropin-releasing hormone (TRH) in patients with amyotrophic lateral sclerosis (ALS) and in motor neuron disease of wobbler mice. In: Tsubaki T, Yase Y (eds) Amyotrophic lateral sclerosis. Elsevier, Amsterdam, pp 295–300

    Google Scholar 

  • Mitsumoto H (1993) Motor neuron disease: the path to clinical trials. Course syllabus. In: Brooke MH (course director) Update on neuromuscular disease. American Academy of Neurology, New York

    Google Scholar 

  • Mitsumoto H, Bradley WG (1982) Murine motor neuron disease (the wobbler mouse). Degeneration and regeneration of the lower motor neuron. Brain 105: 811–834

    Google Scholar 

  • Mitsumoto H, Salgado ED, Negrosky D et al. (1986) Amyotrophic lateral sclerosis: effects of acute intravenous and chronic subcutaneous administration of thyrotropin-releasing hormone in controlled trials. Neurology 36: 152–159

    PubMed  CAS  Google Scholar 

  • Mitsumoto H, Hanson MR, Chad DA (1988) Amyotrophic lateral sclerosis: recent advances in pathogenesis and therapeutic trials. Arch Neurol 45: 189–202

    PubMed  CAS  Google Scholar 

  • Mitsumoto H, Kumar S, Levin KH et al. (1992) Intravenous immunoglobulin treatment in amyotrophic lateral sclerosis. Ann Neurol 32: 252

    Google Scholar 

  • Mitsumoto H, Ikeda K, Greene T, Wong V, Lindsay RM, Cedarbaum JM (1994) The effects of ciliary neurotrophic factor (CNTF) in wobbler mouse motor neuron disease. Ann Neurol (in press).

    Google Scholar 

  • Modarres-Sadeghi H, Rogers H, Emami J, Guiloff RJ (1988) Subacute administration of a TRH analogue (RX77368) in motoneurone disease. An open study. J Neurol Neurosurg Psychiatry 51: 1146–1157

    Google Scholar 

  • Mora JS, Munsat TL, Kao Ko-Pei et al. (1986) Intrathecal administration of natural human interferon alpha in amyotrophic lateral sclerosis. Neurology 36: 1137–1140

    PubMed  CAS  Google Scholar 

  • Munsat TL (1988) Negative drug trial bias. Letter to editor. Neurology 38: 165

    PubMed  CAS  Google Scholar 

  • Munsat TL, Schmidt-Easterday C, Levy S, Wolff SM, Hiatt R (1981) Amantadine and guanidine are ineffective in ALS. Neurology 31: 1054–1055

    PubMed  CAS  Google Scholar 

  • Munsat TL, Brooks BR (1987) Don’t throw out the baby with the bathwater. Letter to the editor. Neurology 37: 544

    Google Scholar 

  • Munsat TL, Andres PL, Finison L, Conlon T, Thibodeau L (1988) The natural history of motoneuron loss in amyotrophic lateral sclerosis. Neurology 38: 409–413

    PubMed  CAS  Google Scholar 

  • Munsat TL, Lechan R, Taft JM, Jackson IMD, Reichlin S (1989) TRH and diseases of the motor system. Ann NY Acad Sci 553: 388–398

    PubMed  CAS  Google Scholar 

  • Nakanishi S (1992) Molecular diversity of glutamate receptors and implications for brain function. Science 258: 597–603

    PubMed  CAS  Google Scholar 

  • The National TRH Study Group (1989) Multicenter controlled trial: no effect of alternate-day 5 mg/kg subcutaneous thyrotropin-releasing hormone (TRH) on isometric-strength decrease in amyotrophic lateral sclerosis. Neurology 39 (Suppl 1): 478

    Google Scholar 

  • Neville HE, Roelofs JI, Smith SA et al. (1986) Treatment of ALS patients with intravenous MK-711 ( A TRH analog) does not improve muscle strength. Muscle Nerve 9: 104

    Google Scholar 

  • Nobile-Orazio E, Carpo M, Legname G et al. (1990) Anti-GMl IgM antibodies in motor neuron disease and neuropathy. Neurology 40: 1747–1750

    PubMed  CAS  Google Scholar 

  • Norris FH, Calanchini PR, Fallat RJ, Panchari S, Jewett B (1974) The administration of guanidine in amyotrophic lateral sclerosis. Neurology 24: 721–728

    PubMed  Google Scholar 

  • Norris FH, Denys EH, Sang UK (1979) Old and new clinical problems in amyotrophic lateral sclerosis. In: Tsubaki T, Toyokura Y (eds) Amyotrophic lateral sclerosis. University Park Press, Baltimore, pp 3–26

    Google Scholar 

  • Norris FH, Denys EH, Fallat RJ (1986) Trial of octacosanol in amyotrophic lateral sclerosis. Neurolbgy 36: 1263–1264

    CAS  Google Scholar 

  • Olanow CW (1992) An introduction to the free radical hypothesis in Parkinson’s disease. Ann Neurol 32: S2–S9

    PubMed  CAS  Google Scholar 

  • Olarte MR, Schoenfeldt RS, McKiernan G, Rowland LP (1980) Plasmapheresis in amyotrophic lateral sclerosis. Ann Neurol 8: 644

    PubMed  CAS  Google Scholar 

  • Olarte MR, Shafer SQ (1985) Levamisole is ineffective in the treatment of amyotrophic lateral sclerosis. Neurology 35: 1063–1066

    PubMed  CAS  Google Scholar 

  • Oppenheim RW, Prevette D, Qin-Wei Y et al. (1991) Control of embryonic motor neuron survival in vivo by ciliary neurotrophic factor ( CNTF ). Science 251: 1616–1618

    PubMed  CAS  Google Scholar 

  • Overgaard K, Werdelin L, Sorensen H et al. (1991) Cytotoxic activity in plasma from patients with amyotrophic lateral sclerosis. Neurology 41: 925–927

    PubMed  CAS  Google Scholar 

  • Parry GJ, Clarke S (1988) Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease. Muscle Nerve 11: 103–107

    PubMed  CAS  Google Scholar 

  • Parry GJ, Holtz SJ, Ben-Zeev D, Drori JB (1986) Gammopathy with proximal motor axonopathy simulating motor neuron disease. Neurology 36: 273–276

    PubMed  CAS  Google Scholar 

  • Patten BM (1984) Neuropathy and motor neuron syndromes associated with plasma cell disease. Acta Neurol Scand 69: 47–61

    Google Scholar 

  • Patten BM (1988) ALS associated with aluminum intoxication. In: Tsubaki T, Yase Y (eds) Amyotrophic lateral sclerosis. Elsevier, Amsterdam, pp 51–58

    Google Scholar 

  • Patten BM, Harati Y, Acosta L, Lung S, Felmus MT (1978) Free amino acid levels in amyotrophic lateral sclerosis. Ann Neurol 3: 305–309

    PubMed  CAS  Google Scholar 

  • Patten BM, Klein LM (1988) 1-Threonine and modification of ALS. Neurology 38(Suppl 1):355

    Google Scholar 

  • Patterson PH (1992) The emerging neuropoietic cytokine family: first CDF/LIF, CNTF and IL-6; next ONC, MGF, GCSF? Curr Opin Neurobiol 2: 94–97

    PubMed  CAS  Google Scholar 

  • Perl DP, Gajdusek DC, Garruto RM et al. (1982) Intraneuronal aluminum accumulation in amyotrophic lateral sclerosis and parkinsonism-dementia of Guam. Science 217: 1053–1055

    PubMed  CAS  Google Scholar 

  • Perry TL, Krieger C, Hansen S et al. (1990) Amyotrophic lateral sclerosis amino acid levels in plasma and cerebrospinal fluid. Ann Neurol 28: 12–17

    PubMed  CAS  Google Scholar 

  • Pestronk A (1991) Invited review. Motor neuropathies, motor neuron disorders, and antiglycolipid antibodies. Muscle Nerve 14: 927–936

    PubMed  CAS  Google Scholar 

  • Pestronk A, Adams RN, Clawson L (1988a) Serum antibodies to GM1 ganglioside in amyotrophic lateral sclerosis. Neurology 38: 1457–1461

    PubMed  CAS  Google Scholar 

  • Pestronk A, Cornblath DR, Ilyas A A et al. (1988b) A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 24: 73–78

    PubMed  CAS  Google Scholar 

  • Pestronk A, Adams RN, Cornblath D et al. (1989) Patterns of serum IgM antibodies to GM1 and GDIa gangliosides in amyotrophic lateral sclerosis. Ann Neurol 25: 98–102

    PubMed  CAS  Google Scholar 

  • Peters HA, Clatanoff DV (1968) Spinal muscular atrophy secondary to macroglobulinemia: reversal of symptoms with chlorambucil therapy. Neurology 18: 101–108

    Google Scholar 

  • Plaitakis A (1990) Glutamate dysfunction and selective motor neuron degeneration in amyotrophic lateral sclerosis: a hypothesis. Ann Neurol 28: 3–8

    PubMed  CAS  Google Scholar 

  • Plaitakis A, Berl S, Yahr MD (1982) Abnormal glutamate metabolism in an adult-onset neurological disorder. Science 215: 193–96

    Google Scholar 

  • Plaitakis A, Berl S, Yahr MD (1984) Neurological disorders associated with deficiency of glutamate dehydrogenase. Ann Neurol 15: 144–153

    PubMed  CAS  Google Scholar 

  • Plaitakis A, Caroscio JT (1987) Abnormal glutamate metabolism in amyotrophic lateral sclerosis. Ann Neurol 22: 575–579

    PubMed  CAS  Google Scholar 

  • Plaitakis A, Constantakakis E, Smith J (1988a) The neuroexcitotoxic amino acids glutamate and aspartate are altered in the spinal cord and brain in amyotrophic lateral sclerosis. Ann Neurol 24: 446–449

    PubMed  CAS  Google Scholar 

  • Plaitakis A, Smith J, Mandeli J, Yahr MD(1988b) Pilot trial of branched-chain amino acids in amyotrophic lateral sclerosis. Lancet i: 1015–1018

    Google Scholar 

  • Plaitakis A, Sivak M, Fesdjian CO, Mandeli J (1992) Treatment of amyotrophic lateral sclerosis with branched chain amino acids (BCAA): results of a second study. Neurology 42 (Suppl 3): 454

    Google Scholar 

  • Ramon y Cajal S (1928) Degeneration and regeneration of the nervous system, vol 1. Hafner, New York

    Google Scholar 

  • Ringel SP, Murphy JR, Alderson MK et al. (1993) The natural history of ALS. Neurology 43: 1316–1322

    PubMed  CAS  Google Scholar 

  • Roelofs-Iverson RA, Mulder DW, Elveback LR, Kurland LT, Molgaard CA (1984) ALS and heavy metals: a pilot case-control study. Neurology 34: 393–395

    PubMed  CAS  Google Scholar 

  • Ross SM, Seelig M, Spencer PS (1987) Specific antagonism of excitotoxic action of “uncommon” amino acids assayed in organotypic mouse cortical cultures. Brain Res 425: 120–127

    PubMed  CAS  Google Scholar 

  • Rothstein JD, Kuncl RW, Claawson L et al. (1989) Cerebrospinal fluid excitatory amino acids in amyotrophic lateral sclerosis. Ann Neurol 26: 144

    Google Scholar 

  • Rothstein JD, Tsai G, Kuncl RW et al. (1990) Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 28: 18–25

    PubMed  CAS  Google Scholar 

  • Rothstein JD, Martin LJ, Kuncl RW (1992) Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 326: 1464–1468

    PubMed  CAS  Google Scholar 

  • Rowland LP (1988a) To the Editor (in reply to letter to editor by Munsat TL: Negative drug trial bias). Neurology 38: 165–166

    Google Scholar 

  • Rowland LP (1988b) Research progress in motor neuron diseases. Rev Neurol 144: 623–629

    PubMed  CAS  Google Scholar 

  • Rowland LP (1992) Amyotrophic lateral sclerosis and autoimmunity. N Engl J Med 327: 1752–1753

    PubMed  CAS  Google Scholar 

  • Rowland LP, Defendini R, Sherman W et al. (1982) Macroglobulinemia with peripheral neuropathy simulating motor neuron disease. Ann Neurol 11: 532–536

    PubMed  CAS  Google Scholar 

  • Rudnicki S, Chad DA, Drachman DA et al. (1987) Motor neuron disease and paraproteinemia. Neurology 37: 335–337

    PubMed  CAS  Google Scholar 

  • Sadiq SA, Thomas EP, Kilidireas K et al. (1990) The spectrum of neurological disease associated with anti-GM antibodies. Neurology 40: 1067–1072

    PubMed  CAS  Google Scholar 

  • Saida T, Saida K, Imoto K, Nishitani H, Sobue I (1988) Trials of thyrotropin-releasing hormone treatment of amyotrophic lateral sclerosis in Japan. In: Tsubaki T, Yase Y (eds) Amyotrophic lateral sclerosis. Elsevier, Amsterdam, pp 301–306

    Google Scholar 

  • Santoro M, Thomas FP, Fink ME et al. (1990) IgM deposits at nodes of Ranvier in a patient with amyotrophic lateral sclerosis, anti-GM1 antibodies, and multifocal motor conduction block. Ann Neurol 28: 373–377

    PubMed  CAS  Google Scholar 

  • Santoro M, Uncini A, Corbo M et al. (1992) Experimental conduction block induced by serum from a patient with anti-GM1 antibodies. Ann Neurol 32: 487–493

    PubMed  Google Scholar 

  • Schluep M, Steck A J (1988) Immunostaining of motor nerve terminals by IgM M protein with activity against gangliosides GM1 and GDlb from a patient with motor neuron disease. Neurology 38: 1890–1892

    PubMed  CAS  Google Scholar 

  • Schmalbruch H, Jensen H-JS, Bjaerg M et al. (1991) A new mouse mutant with progressive motor neuronopathy. J Neuropathol Exp Neurol 50: 192–204

    PubMed  CAS  Google Scholar 

  • Schmidt-Achert KM, Askanas V, Engel WK (1984) Thyrotropin-releasing hormone enhances choline acetyltransferase and creatine kinase in cultured spinal ventral horn neurons. J Neurochem 43: 586–589

    PubMed  CAS  Google Scholar 

  • Sendtner M, Kreutzberg GW, Thoenen H (1990) Ciliary neurotrophic factor prevents the degeneration of motor neurons after axotomy. Nature 345: 440–441

    PubMed  CAS  Google Scholar 

  • Sendtner M, Arakawa Y, Stockli KA et al. (1991) Effect of ciliary neurotrophic factor ( CNTF) on motoneuron survival. J Cell Sci 15: 103–109

    CAS  Google Scholar 

  • Sendtner M, Schmalbruch H, Stockli KA et al. (1992) Ciliary neurotrophic factor prevents degeneration of motor neurons in mouse mutant progressive motor neuronopathy. Nature 358: 502–504

    PubMed  CAS  Google Scholar 

  • Serratrice G, Desnuelle C, Guelton C et al. (1985) Clinical evaluation of thyrotropin releasing hormone in amyotrophic lateral sclerosis. Press Med 14: 487–488

    CAS  Google Scholar 

  • Serratrice G, Desnuelle C, Crevat A, Guelton C, Meyer-Dutour A (1986) Treatment of amyotrophic lateral sclerosis with thyrotropin releasing hormone ( TRH ). Rev Neurol 142: 133–139

    Google Scholar 

  • Shy ME, Rowland LP, Smith T et al. (1986) Motor neuron disease and plasma cell dyscrasia. Neurology 36: 1429–1436

    PubMed  CAS  Google Scholar 

  • Shy ME, Evans VA, Lublin FD et al. (1989) Antibodies to GM1 and GDlb in patients with motor neuron disease without plasma cell dyscrasia. Ann Neurol 25: 511–513

    PubMed  CAS  Google Scholar 

  • Smith RA, Norris FH (1988) Treatment of amyotrophic lateral sclerosis with interferon. In: Smith RA (ed): Interferon treatment of neurologic disorders. Marcel Dekker, New York, pp 265–275

    Google Scholar 

  • Smith RA, Melmed S, Sherman B, Frane J, Munsat TL, Festoff BW (1993) Recombinant growth hormone treatment of amyotrophic lateral sclerosis. Muscle Nerve 16: 624–633

    PubMed  CAS  Google Scholar 

  • Smith RG, Hamilton S, Hofmann F et al. (1992) Serum antibodies to 1-type calcium channels in patients with amyotrophic lateral sclerosis. N Engl J Med 327: 1271–1728

    Google Scholar 

  • Snider SR (1984) Octacosanol in parkinsonism. Ann Neurol 16: 723

    PubMed  CAS  Google Scholar 

  • Snider WD, Johnson EM Jr (1989) Neurotrophic molecules. Ann Neurol 26: 489–506

    PubMed  CAS  Google Scholar 

  • Spencer PS (1987) Guam ALS/parkinsonism-dementia: a long-latency neurotoxic disorder caused by “slow toxin(s)” in food? Can J Neurol Sci 14: 347–357

    PubMed  CAS  Google Scholar 

  • Spencer PS, Ludolph A, Dwivedi MP et al. (1986) Lathyrism: evidence for role of the neuroexcitatory amino acid BOAA. Lancet ii: 1066–1067

    Google Scholar 

  • Spencer PS, Nunn PB, Hugon J et al. (1987) Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neurotoxin. Science 237: 517–522

    PubMed  CAS  Google Scholar 

  • Spencer PS, Allen CN, Kisby GE et al. (1991) Lathyrism and Western Pacific amyotrophic lateral sclerosis: etiology of short and long latency motor system disorders. Adv Neurol 56: 287–299

    PubMed  CAS  Google Scholar 

  • Stober T, Schmrigk K, Dietzsch S, Thielen T (1985) Intrathecal thyrotropin-releasing hormone therapy of amyotrophic lateral sclerosis. J Neurol 32: 13–14

    Google Scholar 

  • Strong MJ, Garruto RM (1991) Chronic aluminum-induced motor neuron degeneration: clinical, neuropathological and molecular biological aspects. Can J Neurol Sci 18: 428–431

    PubMed  CAS  Google Scholar 

  • Sufit SR, Clough JA, Schram M et al. (1987) Isokinetic assessment in ALS. Neurol Clin 5: 197–212

    PubMed  CAS  Google Scholar 

  • Teitelbaum JS, Zatorre RJ, Carpenter S (1990) Neurological sequelae of domoic acid intoxication due to ingestion of mussels from Prince Edward Island. N Engl J Med 322: 1781–1787

    PubMed  CAS  Google Scholar 

  • Testa D, Caraceni T, Fetoni V et al. (1989) Branched-chain amino acids in the treatment of amyotrophic lateral sclerosis. J Neurol 236: 445–447

    PubMed  CAS  Google Scholar 

  • Testa D, Caraceni T, Fetoni V et al. (1992) Chronic treatment with L-threonine in amyotrophic lateral sclerosis: a pilot study. Clin Neurol Neurosurg 94: 7–10

    PubMed  CAS  Google Scholar 

  • Thoenen H (1991) The changing scene of neurotrophic factors. Trends in Neurosci 14: 165–170

    CAS  Google Scholar 

  • Troost D, van den Oord JJ, deLong JM, Swaab DF (1989) Lymphocytic infiltration in the spinal cord of patients with amyotrophic lateral sclerosis. Clin Neuropathol 8: 289–294

    PubMed  CAS  Google Scholar 

  • Uchitel OD, Appel SH, Crawford F, Sczupak L (1988) Immunoglobulins from amyotrophic lateral sclerosis patients enhance spontaneous transmitter release from motor-nerve terminals. Proc Natl Acad Sci USA 85: 7371–7374

    PubMed  CAS  Google Scholar 

  • Uchitel OD, Scornik F, Protti DA et al. (1992) Long-term neuromuscular dysfunction produced by passive transfer of amyotrophic lateral sclerosis immunoglobulins. Neurology 42: 2175–2180

    PubMed  CAS  Google Scholar 

  • Van Den Bergh P, Kelly JJ, Adelman L, Munsat TL, Jackson IMD (1987) Effect of spinal cord TRH deficiency on lower motor neuron function in the rat. Muscle Nerve 10: 397–405

    PubMed  Google Scholar 

  • Weiner LP (1980) Possible role of androgen receptors in amyotrophic lateral sclerosis: a hypothesis. Arch Neurol 37: 129–131

    PubMed  CAS  Google Scholar 

  • Werdelin L, Boysen G, Jensen TS et al. (1990) Immunosuppressive treatment of patients with amyotrophic lateral sclerosis. Acta Neurol Scand 82: 132–134

    PubMed  CAS  Google Scholar 

  • Whitehouse PJ, Wamsley JK, Zarbin MA et al. (1983) Amyotrophic lateral sclerosis: alterations in neurotransmitter receptors. Ann Neurol 14: 8–16

    PubMed  CAS  Google Scholar 

  • Wolfgram F, Myers L (1972) Toxicity of serum from patients with amyotrophic lateral sclerosis for anterior horn cells in vitro. Trans Am Neurol Assoc 97: 19–23

    Google Scholar 

  • Wong V, Arraiga R, Lindsay RM (1990) Effects of ciliary neurotrophic factor ( CNTF) on ventral spinal cord neurons in culture. Soc Neurosci Abstr 16: 484

    Google Scholar 

  • Wong V, Arraiga R, Lindsay RM et al. (1991) Ciliary neurotrophic factor (CNTF) supports survival of motor neurons in culture. Neurology 41 (Suppl 1): 312

    Google Scholar 

  • Yamane K, Osawa M, Kobayashi I, Maruyama S (1986) Treatment of amyotrophic lateral sclerosis with thyrotropin releasing hormone. Jpn J Psychiatry Neurol 40: 179–187

    PubMed  CAS  Google Scholar 

  • Yanagihara RT (1982) Heavy metals and essential minerals in motor neuron disease. Adv Neurol 36: 235–247

    Google Scholar 

  • Yase Y (1984) Metal metabolism in motor neuron disease. In: Chem KM, Yase Y (eds) Amyotrophic lateral sclerosis in Asia and Oceania. National Taiwan University Press, Taipei, pp 337–356

    Google Scholar 

  • Yielding KL, Tomkins GM (1961) An effect of L-leucine and other essential amino acids on the structure and activity of glutamate dehydrogenase. Proc Natl Acad Sci USA 47: 983

    PubMed  CAS  Google Scholar 

  • Young AB (1990) What’s the excitement about excitatory amino acids in amyotrophic lateral sclerosis? Ann Neurol 28: 9–11

    PubMed  CAS  Google Scholar 

  • Younger DS, Rowland LP, Latov N et al. (1990) Motor neuron disease and amyotrophic lateral sclerosis: relation of high CSF protein content to paraproteinemia and clinical syndromes. Neurology 40: 595–599

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. H. Mitsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University Department of Neurology, Institute of Psychiatry and Kings College School of Medicine and Dentistry, De Crespigny Park, London, SE5 8AF, UK

    P. N. Leigh BSc, PhD, FRCP (Professor) (Professor)

  2. Department of Neurology, The Royal London Hospital, Whitechapel, London, E1 1BB, UK

    Michael Swash MD, FRCP, FRCPath (Consultant Neurologist) (Consultant Neurologist)

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer-Verlag London Limited

About this chapter

Cite this chapter

Mitsumoto, H. (1995). New Therapeutic Approaches: Rationale and Results. In: Leigh, P.N., Swash, M. (eds) Motor Neuron Disease. Springer, London. https://doi.org/10.1007/978-1-4471-1871-8_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-1871-8_18

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-1873-2

  • Online ISBN: 978-1-4471-1871-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation